Menu
Search
|

Menu

Close
X

Protagonist Therapeutics Inc PTGX.OQ (NASDAQ Stock Exchange Global Market)

13.16 USD
-- (--)
As of Mar 20
chart
Previous Close 13.16
Open --
Volume --
3m Avg Volume 33,222
Today’s High --
Today’s Low --
52 Week High 21.17
52 Week Low 5.51
Shares Outstanding (mil) 23.35
Market Capitalization (mil) 307.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
31
FY17
20
FY16
0
EPS (USD)
FY18
-1.725
FY17
-2.165
FY16
-2.574
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
9.94
8.99
Price to Book (MRQ)
vs sector
2.71
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-33.20
12.11
Return on Equity (TTM)
vs sector
-33.39
13.22

EXECUTIVE LEADERSHIP

Harold Selick
Independent Chairman of the Board, Since
Salary: --
Bonus: --
Dinesh Patel
President, Chief Executive Officer, Interim Principal Financial Officer, Director, Since 2019
Salary: $475,000.00
Bonus: --
Suneel Gupta
Executive Vice President of Clinical Operations and Clinical Pharmacology, Since 2019
Salary: --
Bonus: --
Niall Murphy
Interim Principal Accounting Officer, Vice President, Controller, Since 2019
Salary: --
Bonus: --
David Liu
Chief Scientific Officer, Head of Research & Development, Since 2016
Salary: $357,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7707 Gateway Blvd Ste 140
NEWARK   CA   94560-1160

Phone: +1510.4740170

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

SPONSORED STORIES